Citation:
Curr Opin Mol Ther. 2004 Oct;6(5):551-8
Abstract:
AVI BioPharma is developing AVI-4126, an antisense oligonucleotide targeted to c-myc mRNA for the potential treatment of restenosis, cancer and polycystic kidney disease. AVI-4126 is currently undergoing phase II clinical trials.